Shares of Salarius Pharmaceuticals (SLRX) were up over 151% Monday after the company said it and Decoy Therapeutics agreed to a merger deal to create a new company in which Salarius and Decoy investors will respectively hold 14% and 86% of the combined company's outstanding shares.
Salarius' wholly-owned unit will merge with Decoy and the newly formed company will operate as Decoy Therapeutics, according to the statement.
Decoy Chief Executive Officer Frederick Pierce, Chief Scientific Officer Barbara Hibne and Salarius' Chief Financial Officer Mark Rosenblum will be part of the combined company's leadership team.
Price: 3.93, Change: +2.37, Percent Change: +151.92
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.